Atopic Dermatitis patient


We are leading the science in immunology through our research and development of advanced treatments for chronic, difficult to treat inflammatory diseases.

With two treatments on the market and a robust pipeline, Immunology is a strong area of growth for us and one in which we have already made a significant impact on the lives of patients. In collaboration with Regeneron, we have a first in class treatment for adults, adolescents and children (6-11 years of age) with moderate-to-severe atopic dermatitis, adults and adolescents with moderate-to-severe asthma, and for adults with chronic rhinosinusitis with nasal polyposis (CRSwNP), three chronic and difficult to treat diseases driven by underlying type 2 inflammation. Our second treatment is for adults with moderate-to-severe rheumatoid arthritis (RA), a chronic and painful inflammatory disorder that damages the joints. Our pipeline includes diseases driven by allergic and other type 2 inflammation, including eosinophilic esophagitis, Chronic Obstructive Pulmonary Disease (COPD), environmental and food allergies, as well as programs focused on juvenile idiopathic arthritis, giant cell arteritis, and polymyalgia rheumatica.

Above from left to right: Gerard, rheumatoid arthritis, France; Miwako, atopic dermatitis, Japan; Jeff, asthma, Canada

Understand AD logo
Atopic dermatitis: From education to empowerment

Understand AD is a national awareness campaign focused on educating people about moderate-to-severe atopic dermatitis (AD), a chronic form of eczema that can be serious. By educating people about the physical and quality of life impact of atopic dermatitis, Understand AD will give a voice to and empower the people living with the disease.

This website uses cookies to track its audience and improve its content. By continuing to browse this website, you agree to the use of such cookies.

Click here for more information on cookies.